Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation

Molecular Immunology

Volumn 66, Issue 2, 2015, Pages 164-170

  Blom, Anna M ^a   Österborg, Anders ^b,c   Mollnes, Tom E ^d,e,f,g,h   Okroj, Marcin ^a,i  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f NLSH   (Norway)

^g UNIVERSITY OF TROMSØ   (Norway)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ Lund University   (Sweden)

Author keywords

Antibodies; C4d; C5b; Complement system; Leukemia; Lymphoma

Indexed keywords

BENDAMUSTINE; BLOCKING ANTIBODY; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOPHOSPHAMIDE; DOXORUBICIN; ECULIZUMAB; EPITOPE; FLUDARABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C4D; MONOCLONAL ANTIBODY C5B; OFATUMUMAB; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; ANTIBODY; ANTINEOPLASTIC AGENT; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CARBOXY TERMINAL SEQUENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; BLOOD; CHEMISTRY; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN DEGRADATION; RABBIT; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPLEMENT ACTIVATION; COMPLEMENT C4B; COMPLEMENT C5B; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC NEOPLASMS; HUMANS; PEPTIDE FRAGMENTS; PROTEOLYSIS; RABBITS; SENSITIVITY AND SPECIFICITY;

EID: 84924958505     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.02.029     Document Type: Article

References (25)

1. Ajona D., Pajares M.J., Corrales L., Perez-Gracia J.L., Agorreta J., Lozano M.D., Torre W., Massion P.P., de-Torres J.P., Jantus-Lewintre E., Camps C., Zulueta J.J., Montuenga L.M., Pio R. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl. Cancer Inst. 2013, 105:1385-1393.
2. Bergseth G., Ludviksen J.K., Kirschfink M., Giclas P.C., Nilsson B., Mollnes T.E. An international serum standard for application in assays to detect human complement activation products. Mol. Immunol. 2013, 56:232-239.
3. Bisschops L.L., Hoedemaekers C.W., Mollnes T.E., van der Hoeven J.G. Rewarming after hypothermia after cardiac arrest shifts the inflammatory balance. Crit. Care Med. 2012, 40:1136-1142.
4. Blom A.M., Volokhina E.B., Fransson V., Stromberg P., Berghard L., Viktorelius M., Mollnes T.E., Lopez-Trascasa M., van den Heuvel L.P., Goodship T.H., Marchbank K.J., Okroj M. A novel method for direct measurement of complement convertases activity in human serum. Clin. Exp. Immunol. 2014, 178:142-153.
5. Cohen D., Colvin R.B., Daha M.R., Drachenberg C.B., Haas M., Nickeleit V., Salmon J.E., Sis B., Zhao M.H., Bruijn J.A., Bajema I.M. Pros and cons for C4d as a biomarker. Kidney Int. 2012, 81:628-639.
6. Dahlback B., Hildebrand B., Malm J. Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. J. Biol. Chem. 1990, 265:8127-8135.
7. Flechner S.M., Fatica R., Askar M., Stephany B.R., Poggio E., Koo A., Banning S., Chiesa-Vottero A., Srinivas T. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010, 90:1486-1492.
8. Gou S.J., Yuan J., Chen M., Yu F., Zhao M.H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013, 83:129-137.
9. Grumach A.S., Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol. Immunol. 2014, 61:110-117.
10. Hadders M.A., Bubeck D., Roversi P., Hakobyan S., Forneris F., Morgan B.P., Pangburn M.K., Llorca O., Lea S.M., Gros P. Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep. 2012, 1:200-207.
11. Jenei Z.M., Zima E., Csuka D., Munthe-Fog L., Hein E., Szeplaki G., Becker D., Karadi I., Prohaszka Z., Garred P., Merkely B. Complement activation and its prognostic role in post-cardiac arrest patients. Scand. J. Immunol. 2014, 79:404-409.
12. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
13. Manzi S., Rairie J.E., Carpenter A.B., Kelly R.H., Jagarlapudi S.P., Sereika S.M., Medsger T.A., Ramsey-Goldman R. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum. 1996, 39:1178-1188.
14. Nelson C.A., Vidavsky I., Viner N.J., Gross M.L., Unanue E.R. Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules. PNAS 1997, 94:628-633.
15. Nilsson S.C., Sim R.B., Lea S.M., Fremeaux-Bacchi V., Blom A.M. Complement factor I in health and disease. Mol. Immunol. 2011, 48:1611-1620.
16. Okroj M., Eriksson I., Osterborg A., Blom A.M. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement. Med. Oncol. 2013, 30:759.
17. Okroj M., Osterborg A., Blom A.M. Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat. Rev. 2013, 39:632-639.
18. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 2007, 25:1256-1264.
19. Sansonno D., Tucci F.A., Ghebrehiwet B., Lauletta G., Peerschke E.I., Conteduca V., Russi S., Gatti P., Sansonno L., Dammacco F. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J. Immunol. 2009, 183:6013-6020.
20. Sim R.B., Tsiftsoglou S.A. Proteases of the complement system. Biochem. Soc. Trans. 2004, 32:21-27.
21. Sudzius G., Mieliauskaite D., Siaurys A., Viliene R., Butrimiene I., Characiejus D., Dumalakiene I. Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjogren's syndrome?. Rheumatol. Int. 2014, 34:235-241.
22. Taylor R.P., Lindorfer M.A. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol. Pharmacol. 2014, 86:485-491.
23. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058-1066.
24. Webster R.O., Larsen G.L., Henson P.M. In vivo clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits. J. Clin. Investig. 1982, 70:1177-1183.
25. Wong E.K., Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl. Res. 2015, 165:306-320.